IPR & Legal

Insulin producers accused of price manipulation

The US law firm, Hagens Berman Sobol Shapiro LLP, has filed a class action suit against Sanofi SA, Novo Nordisk A/S and Eli Lilly and Company alleging that they have used increasingly wider discounts from the list price of their analogue insulins to gain favour with pharmacy benefit managers and health insurers and thereby gained market share.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United States

Cross-consent accord for Charpentier IP

Four companies with rights to intellectual property (IP) generated by Emmanuelle Charpentier and colleagues for the gene editing technology CRISPR/Cas9 have reached an agreement under which rights to the technology given by one member of the group will mean consent from the others.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Ireland

EMA appeals against document ruling

The European Medicines Agency has appealed against a court order preventing it from releasing documents relating to two marketed medicines, arguing that the disclosures are consistent with its policy on transparency.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom

Lundbeck fine upheld; company ponders appeal

In a decision on 8 September, the General Court of the European Union has upheld €150 million of fines imposed by the European Commission on H. Lundbeck A/S and four generic companies for what it says were infringements of competition law.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Denmark

Merus beats Regeneron at law

Merus BV of the Netherlands has secured another legal victory over Regeneron Pharmaceuticals Inc in a battle over intellectual property rights to transgenic mouse technology for the production of therapeutic antibodies.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Netherlands

Merus secures US patent victory

Merus BV has successfully fought off a patent infringement lawsuit brought against it in the US by Regeneron Pharmaceuticals Inc, thus securing freedom to operate in the space for transgenic-mouse based antibody therapeutics. The Dutch company announced the decision on 5 January 2015.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Netherlands

ECJ decision removes threat to stem cell research

The Court of Justice of the European Union has issued a decision in a patent case brought by a US corporation which gives a fresh interpretation to restrictions laid down in 2011 on the patentability of human embryos for industrial or commercial purposes.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Luxembourg

Regeneron to appeal against patent decision

Regeneron Pharmaceuticals Inc is to appeal against a decision of the European Patent Office (EPO) to revoke its patent for transgenic mouse technology, a patent that was successfully challenged by Kymab Ltd of the UK.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United States

Kymab succeeds in patent challenge

Kymab Ltd has successfully challenged a European patent issued to its competitor, Regeneron Pharmaceuticals Inc, for transgenic mouse technology that is a foundation for developing therapeutic antibodies. The patent was said to lack an inventive step as required by European patent law.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom

Update on the human embryo

The Advocate General of the Court of Justice of the European Union has given a fresh interpretation to restrictions laid down by the court in 2011 on the patentability of human embryos for industrial or commercial purposes. 

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Luxembourg

Syndicate content